Navigation Links
Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
Date:8/6/2012

BETHLEHEM, Pa., Aug. 6, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the company has expanded its existing relationship with Bristol-Myers Squibb Company (NYSE: BMY) by entering into a Master Early Development Collaboration Agreement, which may include multiple feasibility studies and companion diagnostic development projects.  With the signing of this agreement, the companies have already initiated a new companion diagnostic project in an undisclosed field.  Terms of the agreement were not disclosed.

"Saladax is delighted to continue working with Bristol-Myers Squibb to deliver on the promise of personalized medicine," said Kevin M. Harter, president and CEO of Saladax.  "Building on our previous work together, which resulted in clinically valuable Alzheimer's disease assays, we're eager to continue marrying the scientific and clinical knowledge of Bristol-Myers Squibb and Saladax to improve the lives of patients in other clinical areas."

Saladax and Bristol-Myers Squibb originally entered into a collaboration in 2010 for the development of clinical diagnostic tests for Alzheimer's disease to be used in conjunction with the development of certain therapeutic compounds in the Bristol-Myers Squibb pipeline.  In 2011, that partnership was expanded to include a commercial partner, Johnson & Johnson's Ortho Clinical Division.

About Saladax Biomedical, Inc.

Saladax Biomedical develops novel diagnostic assays for the practical delivery of personalized medicine. Our proprietary line of MyCare™ assays improves the efficacy of existing drugs by optimizing the dose administered for each individual patient. Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development.  Three MyCare assays, My5- FU™, MyPaclitaxel™ and MyDocetaxel™, are currently offered to the oncology community in some markets.

The company's MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories. This technology capability also enables Saladax to serve as a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.

The company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania. Saladax is ISO 13485:2003 certified.

Saladax Biomedical, Inc.

Kevin M. Harter

President and Chief Executive Officer

kharter@saladax.com

Media Contact:

Tiberend Strategic Advisors, Inc.

212-827-0020

Andrew Mielach or Claire Sojda

amielach@tiberend.com

csojda@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Nuisance seaweed found to produce compounds with biomedical potential
2. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
3. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
4. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
5. Top young Latin-American scientists named Pew Biomedical Fellows
6. Master molecule may improve stem cell treatment of heart attacks
7. Novo Nordisk and BGI establish global collaboration framework
8. Copernicus Award 2012 for German-Polish collaboration in business information systems
9. Scripps Research Institute announces five-year research collaboration with Bristol-Myers Squibb
10. Grant program to spur new research on Alzheimers disease by encouraging collaboration
11. Building global collaboration for biodiversity intelligence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain cancer ... gave her only a few months to live. Now a paper publishing January ... Rosendahl’s disease and increased both the quantity and quality of her life: Adding ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 The report "Direct-Fed ... Aquatic Animals), Form (Dry and Liquid), and Region - Global Forecast to 2022", ... 934.5 Million in 2016 and projected to reach USD 1,399.6 Million by 2022, ... Reading ... MarketsandMarkets Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... As a graduate student, Scarlet ... pathogens that cause malaria and tuberculosis. Seeing firsthand the ravages those diseases visit ... as an assistant professor of biology and biotechnology at Worcester Polytechnic Institute (WPI), ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... in clinical settings, it is becoming increasingly clear that the evolution and transmission ... methods, the standard in the study of clinical resistance, has vastly underestimated these ...
Breaking Biology Technology: